Navigation Links
InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
Date:11/7/2008

. Closing of the private placement is expected to occur on or about 14 November 2008.

In connection with the private placement, certain insiders of InNexus comprised of some members of the Board and senior management, are expected to participate in the offering for an aggregate of approximately 40% on the same terms and InNexus may pay finders' fees to registered persons in an amount equal to 7% of the proceeds from the sale of the debentures to purchasers referred by such finder in accordance with the policies of the TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is considered to be a related-party transaction as defined under Multilateral Instrument 61-101, however, the transaction is exempt from the formal valuation and minority shareholder approval requirements under the instrument as neither the fair market value of the securities being issued nor the consideration paid exceeds 25 per cent of InNexus' market capitalization.

Upon conversion of the debenture, the common shares will be subject to a four-month "hold period" from the date of conversion under the policies of the TSX Venture Exchange and applicable securities legislation.

About Colorectal Cancer

Colorectal cancer is the third most common cancer found in men and women in the United States and is a term referring to cancer that develops in the colon or rectum. The American Cancer Society estimates that there will be about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer in 2008 in the United States. Combined, they will cause about 49,960 deaths.

One of the leading products available is ERBITUX(R) (cetuximab) marketed by ImClone Systems Incorporated. ImClone recently reported that global net sales of ERBITUX(R) for the first quarter of 2008 grew to $417.3 million, an increase of 12% compared to $371.0 million for the previous quarter and an increase of 36% compared to $306.1 million for the same period l
'/>"/>

SOURCE InNexus Biotechnology Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InNexus Biotechnology Receives Patent Grants in Europe
2. InNexus Biotechnology CEO to Present at the 7th Annual BIO Investor Forum
3. InNexus Biotechnology CEO to Present at BioContactQuebec 2008
4. St. Josephs Hospital and InNexus Biotechnology Enter Collaborative Partnership
5. InNexus Biotechnology Strengthens Patent Team With New Leadership
6. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
7. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
8. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
9. TechConnect World 2009 Matches Tomorrows Technology Solutions with Todays Business Needs for Clean-Technology, Biotechnology and Nanotechnology
10. Lixte Biotechnology Holdings Announces New Appointment to Board of Directors
11. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 GEA Niro Soavi ... top laboratory homogenizer, the PandaPLUS 2000, which is ideal ... , and cell disruption . This compact laboratory ... fruit juices, liquid food, food additives and ingredients as ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting ... brand-neutral, independent consultants, Protocol Networks has recently announced its ... the years, his company has attracted several clients in ... as well as others. With the success of these ...
(Date:1/22/2015)... WI (PRWEB) January 22, 2015 Dr. Greg ... the 12th annual Scripps Natural Supplements Pre-Conference seminar on probiotics ... Conference is an annual continuing education conference for health care ... and included the topic of probiotics in health. Dr. Leyer ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
... Romark Laboratories announced results from its STEALTH C-3 clinical trial, ... genotype 1 chronic hepatitis C.  Study results were presented this afternoon ... American Gastroenterological Association Institute (AGA Institute) during Digestive Disease Week 2010 ... , , ...
... TRIANGLE PARK, N.C. , May 4 Chimerix, ... that Kenneth I. Moch has been appointed President ... Operating Officer in July 2009 , bringing more than ... companies.  Mr. Moch will also join the company,s Board, for ...
... May 4, 2010 Ansell today announced the launch,of their new GAMMEX(R) ... College of Surgeons in, Perth, Australia . , ... It is the first surgical glove which incorporates ... viruses and bacteria, in the event of a breach during,surgery. , ...
Cached Biology Technology:Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 2Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 3Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 4Romark Announces Final Data From Clinical Trial of Nitazoxanide in Treatment-Naive Patients With Genotype 1 Chronic Hepatitis C 5Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 2Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 3Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer 4Ansell Launches Worlds's First Antimicrobial Surgical Glove 2
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
(Date:1/22/2015)... , Jan. 21, 2015  Analyst Report Issued by Small ... Brands report showed that planet-wide, transactions at merchants on the ... the total number of credit, debit, and prepaid cards reached ... were victims of fraudulent card usage in 2012, and credit ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... A recent Montana State University master,s graduate is working ... build a handheld laser microscope that could someday reduce ... Suspicious spots on the skin often prompt dermatologists ... currently the best way to diagnose skin cancers, said ...
... Ill. Stopping to smell the coffee and enjoy ... do more than just get your juices flowing. It might ... As a former competitive cyclist, University of Illinois kinesiology and ... a coffee shop to fuel up on caffeine prior to ...
... breakthrough that could help everyone from bed-ridden patients to elite ... Mario R. Capecchihave created a "switch" that allows mutations or ... to monitor muscle regeneration in a living mammal. For humans, ... that allows people to grow new muscle cells to replace ...
Cached Biology News:Montana State grad's work helps diagnose skin cancer without a biopsy 2Montana State grad's work helps diagnose skin cancer without a biopsy 3A little java makes it easier to jive, researcher says 2A little java makes it easier to jive, researcher says 3A little java makes it easier to jive, researcher says 4Stem cell breakthrough: Monitoring the on switch that turns stem cells into muscle 2
...
Request Info...
Spaced cover glasses to promote effective hybridization...
... Platform combines robust chemistry with optimized ... specific, and cost-effective detection method available ... offers exceptional performance with specificity and ... signal/background ratio, and an expanded array ...
Biology Products: